Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

Q4 2024 Earnings Call Transcript February 26, 2025 United Therapeutics Corporation beats earnings expectations. Reported EPS ...

Reports Q4 revenue $735.9M, consensus $734.74M. “I want to congratulate every Unitherian for their relentless dedication, which has allowed us ...

MannKind’s future hinges on Tyvaso DPI's growth, R&D prospects, and financial stability despite competition and risks.

United Therapeutics Corp (UTHR) reports a third consecutive year of record revenue, strategic clinical advancements, and significant shareholder returns.

Good morning and welcome to the United Therapeutics Corporation, fourth quarter 2024 corporate update. My name is Cindy, and I will be your conference operator today. (Operator Instructions) Please ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Meloxicam is an enolcarboxamide with preferential COX-2 activity. Studies conducted on experimental models and human tissues indicate that meloxicam is a more potent inhibitor of COX-2 than COX-1 ...

Preeclampsia is a risk factor for the development of later‐life cardiovascular disease. However, the underlying mechanisms are poorly understood. Excessive hypercholesteremia in pregnancy induces a ...